Physician profile
Ethan Everlith
NPI 1003391434
$2,097.93
in general payments reported to CMS, 2019-2025
25 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $512 · 2023: $513 · 2024: $473 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.90 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $382.68 | 2022-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $227.91 | 2022-2023 | Zeposia |
| Abbvie INC. | $224.23 | 2021-2025 | |
| Celgene Corporation | $200.29 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $186.13 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.35 | 2021-2023 | Trulance |
| Regeneron Healthcare Solutions, INC. | $150.70 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $97.09 | 2022-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $68.33 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $63.77 | 2021-2023 | Dificid |
| Endogastric Solutions, INC | $49.82 | 2022 | |
| Redhill Biopharma INC. | $31.30 | 2021-2022 | |
| Echosens North America, INC. | $29.31 | 2024 | Fibroscan |
| Alnylam Pharmaceuticals INC. | $24.14 | 2023 | Givlaari |
| Aimmune Therapeutics, INC. | $23.29 | 2025 | Zenpep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $20.75 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $19.96 | 2023 | Rebyota |
| Gilead Sciences, INC. | $19.81 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.75 | 2023 | Cyltezo |
| Genzyme Corporation | $19.15 | 2023 | |
| Intercept Pharmaceuticals, INC. | $18.55 | 2024 | |
| Oxford Immunotec USA INC | $17.66 | 2022 | |
| Pfizer INC. | $15.93 | 2025 | |
| Ironwood Pharmaceuticals, INC | $15.09 | 2023 | Linzess |
| Novo Nordisk INC | $14.94 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Everlith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.